Navigation Links
Merrimack Pharmaceuticals Initiates Enrollment in a Neoadjuvant Phase 2 Study of MM-121 with Paclitaxel in HER2-negative Breast Cancer Patients
Date:10/11/2011

CAMBRIDGE, Mass., Oct. 11, 2011 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a randomized Phase 2 clinical trial of MM-121, a fully human monoclonal antibody that targets ErbB3, combined with paclitaxel (Taxol®) in the neoadjuvant setting of HER2-negative breast cancer patients.

(Logo: http://photos.prnewswire.com/prnh/20100913/NE63515LOGO)

The Phase 2 study is designed to evaluate whether the combination of MM-121 with paclitaxel is more effective than treatment with paclitaxel alone when administered as part of a neoadjuvant treatment regimen in HER2-negative, locally advanced breast cancer patients. A total of 200 patients are expected to be enrolled in the study. Following treatment with MM-121 and paclitaxel, or paclitaxel alone, patients will receive standard treatment with doxorubicin and cyclophosphamide and monitored until surgical resection. Multiple sites in North America are currently expected to participate in this study. The first patient was enrolled at Texas Oncology - Memorial City.

Merrimack entered into an exclusive, global collaboration and licensing agreement with Sanofi for MM-121 in 2009.

About Merrimack

Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. Merrimack applies Network Biology, its proprietary systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has four targeted therapeutic oncology candidates in clinical development and a fifth expected to enter clinical development by early 2012.

Contact: Kathleen Petrozzelli Gallagher, Corporate Communications, Merrimack, 617-441-1043,
kgallagher@merrimackpharma.com
Betsy Stevenson,
'/>"/>

SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. FDA Grants Orphan Drug Status to Merrimack Pharmaceuticals MM-398, a Nanotherapeutic Encapsulation of Irinotecan, for the Treatment of Pancreatic Cancer
2. Merrimack Pharmaceuticals Announces that Recruitment is Open in a Phase 1 Combination Study of MM-111 with Multiple Treatment Regimens in HER2 Positive Patients
3. Merrimack Pharmaceuticals Announces the Addition of Michael Porter to its Board of Directors
4. Merrimack Pharmaceuticals to Present at the 2010 Stifel Nicolaus Healthcare Conference
5. Sanofi-aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM-121, an Anti-ErbB3 Monoclonal Antibody
6. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
7. Inspiration Biopharmaceuticals Names John P. Butler Chief Executive Officer
8. Inovio Pharmaceuticals and VGX International to Advance Therapeutic Hepatitis C and Hepatitis B Synthetic Vaccines into Clinical Studies
9. Inovio Pharmaceuticals Leadership for Life Sciences Recognized in the Philadelphia Region
10. Inovio Pharmaceuticals Synthetic Vaccine for Cancer Recognized as Most Promising Research at Global Vaccine Congress
11. OncoMed Pharmaceuticals Names Dr. Jakob Dupont VP Clinical Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Aufgrund der enormen Nachfrage ... Serialisierungs-Countdown-Kalender aktualisiert, der jetzt auch die Jahre 2014 ... pharmaserialisation.com , zeigt die Serialisierungsanforderungen weltweit und ... treten. Für international tätige Unternehmen geht ... "ob", sondern darum, "wann" sie die neu in ...
(Date:9/19/2014)... Intarcia Therapeutics, Inc. today announced the presentation ... ITCA 650 (continuous subcutaneous delivery of exenatide) in type ... the 50 th Annual Meeting of the European ... the open-label, phase 3 FREEDOM-HBL (high baseline) trial showed ... poorly controlled type 2 diabetes. The results were presented ...
(Date:9/19/2014)... CAMBRIDGE, Mass. , Sept. 19, 2014   ... of advanced cancer genome analysis and testing services, ... discovering and developing highly selective kinase inhibitors for ... genomic study of malignant mixed Mullerian tumors (MMMT), ... reproductive system, also known as carcinosarcoma. The new ...
Breaking Medicine Technology:Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4
... SARcode Corporation presented data today for their lead investigational ... trial, subjects receiving SAR 1118 demonstrated a reduction in ... as compared to placebo. These data were part of ... Vision and Ophthalmology (ARVO) Annual Meeting held in Fort ...
... 3, 2011 At the Board of Directors meeting held ... per share. The dividend is payable on June 15, 2011 ... About Sigma-Aldrich: Sigma-Aldrich is a leading ... to Improve the Quality of Life. Its chemical and biochemical ...
Cached Medicine Technology:SAR 1118 Demonstrates Encouraging Results in Phase 2 Study of Dry Eye Disease 2SAR 1118 Demonstrates Encouraging Results in Phase 2 Study of Dry Eye Disease 3
(Date:9/21/2014)... September 21, 2014 “Cluster headaches are ... intense and difficult to resolve,” said Steve Young of ... think of a pain that is more intense.” , ... from cluster headaches, or migraines, that medical research is ... serotonin system,” he added. , Serotonin (5-HT, 5-hydroxytryptamine) is ...
(Date:9/21/2014)... Viejo, California (PRWEB) September 21, 2014 ... X plugins have announced a new transition plugin ... “Transpack Vol. 3 delivers high quality transitions that will ... project,” said Christina Austin, CEO of Pixel Film Studios. ... 3 is a definite game changer.” , Transpack Vol. ...
(Date:9/21/2014)... (PRWEB) September 21, 2014 C8 lawsuits ... of Ohio as the list of 20 possible ... narrowed down to six, reports Wright & Schulte LLC. ... from the almost 2500 C8 lawsuits filed that represent ... testicular cancer as a result of being exposed to ...
(Date:9/21/2014)... Top10BestSEOHosting.com, a leading review website, ... GreenGeeks are the most recommended hosting suppliers for ... quality hosting products. , “Don’t waste your ... recommend two great hosting companies to you,” the ... iPage and GreenGeeks are the most recommended suppliers ...
(Date:9/20/2014)... Recently, UWDress.com, a professional company of women’s ... its newly announced evening cocktail dresses . As ... occasion outfits are very popular among worldwide customers. Now, ... savings (up to 65 percent off). , All ... special occasion outfits for the global clients. The company ...
Breaking Medicine News(10 mins):Health News:Homeostasis: Equinox Serotonin (5HT) Headache Stories ~ New on the Bryan William Brickner Blog 2Health News:Pixel Film Studios Released Transpack Vol. 3 Plugin Exclusively for Final Cut Pro X 2Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 2Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 3Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 4Health News:Leading Review Website Top10BestSEOHosting.com Unveils The Best Hosting Suppliers In September 2Health News:Cheap Evening Cocktail Dresses Recently Introduced At UWDress.com 2
... explain that a protein often called as the ‘fat ... ,The researchers from the University of Dundee ... cancer, diabetes and obesity. Dr Anil Mehta the head ... that the findings could improve the effectiveness of treatment ...
... reported the findings that adults in their seventies who drank ... live longer and have fewer heart attacks. ,The ... diseases in 1997 and 1998. The subjects were followed for ... consumption is associated with a 26% reduced risk of possible ...
... obsession of MP3 players that blare out music loudly is at ... generation.// Researchers from the Deafness Research, UK, found that 14 to ... 28 hours per week. ,Over a third of the ... sure sign of damage to hearing, after listening to loud music. ...
... to the investigations conducted by the General of ... tested positive for containing harmful drugs in erectile// ... ,After routine investigations Medsafe identified five remedies that ... individuals. Some contained sildenafil, the erectile dysfunction drug ...
... Australia's birth rate has risen since the government sang from ... the country" song sheet and began paying out 3,000 Australian// ... showed. ,But Treasurer Peter Costello wants to hear ... to "procreate and cherish" in order to reverse the declining ...
... care could cause a change in the role of district ... the roles of community health professionals such as health visitors ... affect about 9,000 nurses across Scotland. ,These were ... a major review of the community health sector for the ...
Cached Medicine News:Health News:Protein May Offer New Hope For Treatment Of Cystic Fibrosis 2Health News:Adults In Their Seventies Could Drink Alcohol To Help Against Heart Ailments 2Health News:Australia's Baby Bonus Plan has Increased the Birth Rate 2
Lyphochek Whole Blood Metals Control contains the major heavy metals of toxicological and environmental importance for whole blood analysis....
Lyphochek Urine Metals Control incorporates two levels of critical trace elements, heavy metals and organic metabolites, and is ideal for environmental and industrial testing....
Liquichek Urinalysis Control is specifically designed for urine dipstick and microscopic testing. This control provides clear, visual positive and negative results, including hCG (pregnancy) and micr...
qUAntify Control is designed to monitor the performance of urine dipstick testing. The control is available in 12 mL ready-to-use dropper bottles....
Medicine Products: